Swanson Reed News

HURRY! – 18 DAYS UNTIL R&D TAX INCENTIVES DEADLINE

April 11th, 2013

The April 30 R&D Tax Incentive deadline (for June balancing companies) is fast approaching and companies must ensure they register all R&D activities to be eligible for the 43.5% refundable tax offset. The program is open to firms of all sizes in all sectors who are conducting eligible R&D. If your company has an aggregated turnover of less than $20 million per annum you could be entitled to the cash refund of 43.5% of all eligible costs. Click on our eligibility […]

Read More

Prana Biotechnology in Melbourne has received $5.8 million for clinical research for neurological diseases

April 10th, 2013

Melbourne company Prana Biotechnology has announced it has received a R&D Tax Incentive of A$2.5 million to support its scientific focus upon neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases. The payment is part of approximately A$5.8 million which is expected to be received for the 2011-12 and 2012-13 financial years. “This Australian Government funded program is commendable because it provides significant amounts of non-dilutive cash to support our ongoing research activities.” commented Geoffrey Kempler, Prana’s Chairman and CEO.

Read More

ZBB Energy receives $180,000 R&D Tax Incentive

April 9th, 2013

ZBB Energy Corporation is an industry leader in the design, development and manufacture of energy storage and power control technology. The company’s Australian subsidiary ZBB Energy Pty has announced an AUS$180,000 R&D Tax Incentive Refund for the 2012 fiscal year.  Eric Apfelbach, CEO and President of ZBB Energy said “We appreciate the continued support of the Australian government for our research activities in Australia. Our R&D efforts on new product designs, cost reduction, and performance improvements on our flow battery […]

Read More

Another win for an Australian Business

April 5th, 2013

Australian Biotechnology Company, Spinifex Pharmaceuticals has announced it has received an R&D Tax Incentive of approximately AUS$1.5 million. The Melbourne company established in June 2005 develops new medicinal drugs for the treatment and management of pain. The funds will be reinvested in further clinical development. Spinifex Pharmaceuticals CEO Tom McCarthy said: “This payment under the R&D tax incentive program is a good example of how Government initiatives can support innovative companies in the biotechnology industry and other sectors”. Click here […]

Read More

Bryce Steele
Principal, Melbourne
Tel: (03) 9018 5778
Mob: 0401 997 584
Tom Parkhouse
Principal, Sydney
Tel: (02) 8006 0559
Mob: 0411 718 565
Andy Nguyen
Principal, Brisbane
Tel: (07) 3221 1499
Mob: 0407 750 249
Sophie Mercer
Principal, Adelaide
Tel: (08) 8121 7850
Mob: 0435 713 493
David Greatwich
Principal, Perth
Tel: (08) 9340 3745
Mob: 0468 386 250
Myriam Risch
Manager, Hobart
Tel: (03) 9018 5778
Mob: 0401 262 591

Categories

Archives

Email this job